Syros Pharmaceuticals (SYRS) Receiving Somewhat Favorable News Coverage, Analysis Shows
News articles about Syros Pharmaceuticals (NASDAQ:SYRS) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Syros Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.8344640136368 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Oppenheimer Analysts Give Syros Pharmaceuticals (SYRS) a $28.00 Price Target (americanbankingnews.com)
- Insider Buying: Syros Pharmaceuticals Inc (SYRS) Insider Purchases 15,000 Shares of Stock (americanbankingnews.com)
- Syros Pharmaceuticals Inc (SYRS) Director Srinivas Akkaraju Acquires 109,774 Shares (americanbankingnews.com)
- Syros Pharmaceuticals Inc (SYRS) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Wedbush Equities Analysts Lower Earnings Estimates for Syros Pharmaceuticals Inc (SYRS) (americanbankingnews.com)
Shares of Syros Pharmaceuticals (NASDAQ SYRS) traded up $0.90 during midday trading on Tuesday, hitting $9.89. The company had a trading volume of 934,300 shares, compared to its average volume of 137,377. Syros Pharmaceuticals has a 52 week low of $6.30 and a 52 week high of $24.38.
A number of analysts have recently issued reports on the company. Oppenheimer set a $28.00 price target on Syros Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, December 13th. Cann reiterated a “buy” rating and set a $28.00 price target on shares of Syros Pharmaceuticals in a research report on Monday, August 21st. Zacks Investment Research downgraded Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Cowen reiterated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Monday, December 11th. Finally, JMP Securities upgraded Syros Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $33.00 price target for the company in a research report on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $26.14.
In other news, Director Srinivas Akkaraju acquired 109,774 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were bought at an average cost of $9.03 per share, with a total value of $991,259.22. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, insider Jeremy P. Springhorn acquired 15,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were purchased at an average cost of $9.08 per share, for a total transaction of $136,200.00. The disclosure for this purchase can be found here. Company insiders own 33.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Syros Pharmaceuticals (SYRS) Receiving Somewhat Favorable News Coverage, Analysis Shows” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/syros-pharmaceuticals-syrs-receiving-somewhat-favorable-news-coverage-analysis-shows/1773047.html.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.